Background: Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use.
Aim: To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy).
Material And Methods: Patients with stage IV gastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed.
Results: Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months.
Conclusions: FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFShenqi injection plus probiotics improves nutritional status in patients with gastric cancer after partial gastrectomy.
Pak J Pharm Sci
January 2025
Department of Gastroenterology, Yulin First Hospital, Yulin, Shaanxi, China.
In recent years, the incidence of gastric cancer (GC) has been on the rise, surgical procedures usually require the removal of part of gastric tissue connected with the tumor lesion, which leads to poor postoperative health and adverse prognosis in patients. Probiotics, as an active microorganism, play an important role in improving gastrointestinal function and enhancing immunity. In this study, we randomized 135 GC patients into a control group, a probiotic group and a combination group.
View Article and Find Full Text PDFHealth utility scores of six common cancers in China measured by SF-6Dv2.
Health Qual Life Outcomes
January 2025
School of Health Management, Harbin Medical University, Harbin, 150081, China.
Purpose: Given the recent update of SF-6Dv2, detailed data on utility scores for cancer patients by cancer type remain scarce in China and other regions, which limits the precision of cost-utility analyses (CUA) in cancer interventions. The aim of the study was to systematically evaluate utility scores of six common cancers in China measured using SF-6Dv2, and identify the potential factors associated with utility scores.
Methods: A hospital-based cross-sectional survey was conducted from August 2022 to December 2023.
Background: Immunotherapy is increasingly significant in treating metastatic gastric cancer. This prospective phase 2 study investigates the efficacy and safety of combining nivolumab with chemotherapy in patients with metastatic gastric cancer co-expressing FGFR2 and PD-L1.
Methods: Eligible patients were aged 18 years or older, with previously untreated HER-2 negative, PD-L1 positive, and FGFR2 positive metastatic gastric adenocarcinoma.
Risk assessment for esophageal cancer after bariatric surgery: a comparative cohort study between sleeve gastrectomy and gastric bypass.
Surg Obes Relat Dis
December 2024
Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital Pessac, Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France. Electronic address:
Background: The risk of esophageal cancer after bariatric surgery is a matter of debate.
Objective: This study aims to evaluate the risk of esophageal cancer following sleeve gastrectomy (SG) and gastric bypass (GB).
Methods: We extracted data from the national discharge database (Programme De Médicalisation des Systèmes d'Information) for patients who underwent bariatric surgery in France between 2007 and 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!